Teaching old transition metals new tricks: Chemists activate palladium catalysis by light

March 24, 2020

In the production of compounds, chemists have the fundamental goal of finding strategies that are most selective and avoid waste products. Breakthroughs in this area serve, among other things, to drive industrial innovation and drug development. In this context, allylic substitution reactions using catalysts made of so-called transition metals have already led to significant advances in science. The catalysts cause that in a molecule a functional group is replaced by another group in allylic position, i.e. in direct proximity to a carbon-carbon double bond.

In particular, the so-called allylic functionalization by means of a catalyst based on the transition metal palladium has become a well-established strategy for constructing carbon-carbon or carbon-heteroatom bonds, and its utility has been demonstrated in natural product synthesis, drug discovery and materials science. Nevertheless, there are still considerable challenges in practice, especially with regard to the sustainability of the substances and their ability to undergo chemical reactions.

Now a team of researchers led by Prof. Frank Glorius from the University of Münster (Germany) has developed a new approach to allyl functionalization and generated π-allylpalladium complexes using radical chemistry. The study has been published in the journal "Nature Catalysis".

Several methods had been developed to generate π-allylpalladium complexes through ionic mechanisms before; however, these methods typically require either prefunctionalized starting materials or stoichiometric oxidants, which naturally limits their scope. "This is the first time to achieve the π-allylpalladium complexes using a radical strategy. We hope that this radical strategy will be quickly adopted by the synthetic community and used as a complementary method to enable a number of other related reactions," Prof. Frank Glorius states.

This is how the new method functions: A commercially available palladium catalyst is photoexcited by visible light, merging N-hydroxyphthalimide esters derived from inexpensive and abundant aliphatic carboxylic acids and feedstock butadiene, enabling to generate π-allylpalladium complexes. This leads to a so-called 1,4-aminoalkylation of the dienes, which the scientists were able to show across more than 60 examples. Moreover, they could demonstrate the utility of this strategy in radical cascade reactions and in the modification of drugs and natural products.

"This is an innovation in Palladium chemistry, we taught this old transition metal catalyst new tricks. Additionally, readily available N-hydroxyphthalimide esters were employed as bifunctional reagents, killing two birds using one stone," says Dr. Huan-Ming Huang, first author of the study.
-end-
Original publication:

H.-M. Huang et al. (2020): Catalytic radical generation of π-allylpalladium complexes. Nature Catalysis; DOI: 10.1038/s41929-020-0434-0

University of Münster

Related Drug Development Articles from Brightsurf:

FDA support for oncology drug development during COVID-19
This Viewpoint from the U.S. Food and Drug Administration puts into context recent guidance on clinical trials during COVID-19 for oncology and shares insight regarding regulatory challenges and lessons learned.

COVID-19 drug development could benefit from approach used against flu
A new study from researchers at The University of Texas at Austin has found that some antivirals are useful for more than helping sick people get better -- they also can prevent thousands of deaths and hundreds of thousands of virus cases if used in the early stages of infection.

Chemistry breakthrough could speed up drug development
Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development.

New model of the GI tract could speed drug development
MIT engineers have devised a way to speed new drug development by rapidly testing how well they are absorbed in the small intestine.

Super-charging drug development for COVID-19
Researchers are using cell-free manufacturing to ramp up production of valinomycin, a promising drug that has proven effective in obliterating SARS-CoV in cellular cultures.

Drug development for rare diseases affecting children is increasing
The number of treatments for rare diseases affecting children has increased, a new study suggests.

New opportunity for cancer drug development
After years of research on cell surface receptors called Frizzleds, researchers at Karolinska Institutet in Sweden provide the proof-of-principle that these receptors are druggable by small molecules.

Novel paradigm in drug development
Targeted protein degradation (TPD) is a new paradigm in drug discovery that could lead to the development of new medicines to treat diseases such as cancer more effectively.

Turbo chip for drug development
In spite of increasing demand, the number of newly developed drugs decreased continuously in the past decades.

A breakthrough for brain tumor drug development
Glioblastoma is a devastating disease with poor survival stats due in part to a lack of preclinical models for new drug testing.

Read More: Drug Development News and Drug Development Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.